Interpreting recent trends in prostate cancer incidence and mortality

Epidemiology

Volumn 8, Issue 2, 1997, Pages 117-120

  Gann, Peter H ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

HUMAN; INCIDENCE; MALE; MASS SCREENING; MIDDLE AGED; MORTALITY; NOTE; PROSTATE TUMOR; SURVIVAL RATE; UNITED STATES;

HUMANS; INCIDENCE; MALE; MASS SCREENING; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL RATE; UNITED STATES;

EID: 0031085620     PISSN: 10443983     EISSN: 15315487     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Ries LAG, Miller BA, Hankey BF, Kosary CL, Harras A, Edwards BK. SEER Cancer Statistics Review, 1973-1991 (Tables and Graphs). DHHS Pub. No. (NIH)94'2789. Bethesda, MD: National Cancer Institute, 1994.
2. Merrill RM, Brawley OW. Prostate cancer incidence and mortality rates among white and black men. Epidemiology 1997;8:126-131.
3. Lu-Yao GL, Greenberg ER. Changes in prostate cancer incidence and treatment in USA. Lancet 1994;343:251-254.
4. Potosky AL, Kessler L, Gridley G, Brown CC, Horm JW. Rise in prostate cancer incidence associated with increased use of transurethral resection. J Natl Cancer Inst 1990;82:1624-1628.
5. Lange PH. The next era for prostate cancer. JAMA 1993;269:95-96.
6. Miller AB. Evaluation of the impact of screening for cancer of the cervix. In: Hakama M, Miller AB, Day NE, eds. Screening for Cancer of the Uterine Cervix. Lyon: International Agency for Research on Cancer, 1986; 149-160.
7. Hermon C, Beral V. Breast cancer mortality rates are levelling off or beginning to decline in many western countries: analysis of time trends, age-cohort and age-period models of breast cancer mortality in 20 countries. Br J Cancer 1996;73:956-960.
8. Morrison AS. Intermediate determinants of mortality in the evaluation of screening. Int J Epidemiol 1991;20:642-650.
9. Gilliland FD, Welsh DJ, Hoffman RM, Key CR. Rapid rise and subsequent decline in prostate cancer incidence rates for New Mexico. Cancer Epidemiol Biomarkers Prev 1995;4:797-800.
10. Merrill RM, Potosky AL, Feuer EJ. Changing trends in US prostate cancer incidence rates. J Natl Cancer Inst 1996;88:1683-1685.
11. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995;274:289-294.
12. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tutnor extent of nonpalpable (stage Tic) prostate cancer. JAMA 1994;271:368-374.
13. Labrie F, Candas B, Cusan L, Gômez J-L, Diamond P, Suburu R, LeMay M. Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen. Urology 1996;47:212-217.
14. Smith DS, Catalona WJ, Herschman JD. Longitudinal screening for prostate cancer with prostate-specific antigen. JAMA 1996;276:1309-1315.
15. Merrill RM. Trends in prostate cancer incidence and surgery. J Natl Cancer Inst 1996;88:403.
16. Day NE. Quantitative approaches to the evaluation of screening programs. World J Surg 1989;13:3-8.
17. Miller AB, Chamberlain J, Day NE, Hakama M, Prorok PC. Report on a workshop of the UICC Project on Evaluation of Screening for Cancer. Int J Cancer 1990;46:761-769.
18. Walter SD, Day NE. Estimation of the duration of a preclinical state using screening data. Am J Epidemiol 1983;118:865-886.
19. Sasco AJ, Day NE, Walter SD. Case-control studies for the evaluation of screening. J Chron Dis 1986;39:399-405.